{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:48:57Z","timestamp":1787759337579,"version":"build-2784847793"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"vor","delay-in-days":329,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The inHealth Pilot Project Discovery Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The role of cefepime for extended-spectrum \u03b2-lactamase (ESBL) bacteremia is unclear if susceptible in vitro. In a propensity score-matched study of patients with ESBL bacteremia, risk of death was 2.87 times higher for patients receiving cefepime compared with carbapenems (95% confidence interval [CI], .88\u20139.41). We compared 14-day mortality of patients with ESBL bacteremia receiving empiric cefepime versus empiric carbapenem therapy in a propensity score-matched cohort. There was a trend towards increased mortality in the cefepime group (hazard ratio, 2.87; 95% CI, .88\u20139.41), which enhances the existing literature suggesting that cefepime may be suboptimal for invasive ESBL infections.<\/jats:p>","DOI":"10.1093\/ofid\/ofw132","type":"journal-article","created":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T19:56:40Z","timestamp":1466539000000},"source":"Crossref","is-referenced-by-count":63,"title":["Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum \u03b2-Lactamase-Producing Enterobacteriaceae Bacteremia"],"prefix":"10.1093","volume":"3","author":[{"given":"Ruibin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tschudin-Sutter","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Han","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases and Epidemiology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison E.","family":"Turnbull","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, The Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice J.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Avdic","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Division of Medical Microbiology, The Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita D.","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,20]]},"reference":[{"key":"2020081006272989800_OFW132C1","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u201426th Edition","author":"CLSI","year":"2016"},{"key":"2020081006272989800_OFW132C2","article-title":"Breakpoint Tables for Interpretation of MICs and Sone Diameters. Version 1.1","author":"EUCAST: The European Committee on Antimicrobial Susceptibility Testing"},{"key":"2020081006272989800_OFW132C3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1086\/666632","article-title":"Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests","volume":"33","author":"Marchaim","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020081006272989800_OFW132C4","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/jac\/dkq343","article-title":"High frequency of beta-lactam susceptibility in CTX-M-type extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations","volume":"65","author":"de Oliveira","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020081006272989800_OFW132C5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.diagmicrobio.2005.10.001","article-title":"Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997\u20132004)","volume":"53","author":"Goossens","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081006272989800_OFW132C6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020081006272989800_OFW132C7","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081006272989800_OFW132C8","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"2020081006272989800_OFW132C9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020081006272989800_OFW132C10","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081006272989800_OFW132C11","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/508877","article-title":"Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge","volume":"43","author":"Rodriguez-Bano","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020081006272989800_OFW132C12","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020081006272989800_OFW132C13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1592\/phco.23.12.1232.32706","article-title":"Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period","volume":"23","author":"Burgess","year":"2003","journal-title":"Pharmacotherapy"},{"key":"2020081006272989800_OFW132C14","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081006272989800_OFW132C15","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.45.4.1287-1291.2001","article-title":"In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain","volume":"45","author":"Szabo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081006272989800_OFW132C16","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/AAC.41.5.1053","article-title":"Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae","volume":"41","author":"Thauvin-Eliopoulos","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081006272989800_OFW132C17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkl349","article-title":"Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units","volume":"58","author":"Roos","year":"2006","journal-title":"J Antimicrob Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/3\/3\/ofw132\/33622149\/ofw132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/3\/3\/ofw132\/33622149\/ofw132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T06:38:27Z","timestamp":1597041507000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofw132\/2593274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofw132","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726675611.793549918","asserted-by":"object"}]},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016]]},"published":{"date-parts":[[2016]]},"article-number":"ofw132"}}